DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Henoch-Schoenlein purpura — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHenoch-Schoenlein purpura maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for henoch-schoenlein purpura is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
membrane spanning 4-domains A1 (MS4A1) — MS4A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet y01drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VJA · 3.3 Å · ligand CHOLESTEROL HEMISUCCINATE (Y01). Experimental structure, not a prediction.
What the evidence adds up to
A 1966 report describes a fatal case of Henoch-Schönlein purpura in which death resulted from haemorrhage and necrosis of the entire gastrointestinal tract; autopsy also showed necrotising vasculitis of skin, lungs and gut, focal necrosis of liver and adrenal glands, and membranous glomerulonephritis. The authors state that death from total intestinal infarction in this disease had not been previously described.
A 1958 study of twenty adult patients aged 24 to 76 found symptom frequencies similar to those in children: purpura in 100%, arthralgia in 90%, intestinal bleeding in 57%, and haematuria in 57%. The degree of renal involvement determined the prognosis. An allergic cause was demonstrated in three patients, with sulfa drugs, cow milk, and extracts from B. coli identified as causal antigens. The authors concluded that no particular therapy could be advocated with certainty.
A 2009 case report describes an 11-year-old girl with Henoch-Schönlein purpura who developed severe asymmetric choreic movements and behavioural disturbances two weeks later, diagnosed as Sydenham’s chorea. She received intravenous methylprednisolone for five consecutive days, and both the movement and behavioural disorders resolved rapidly. She remained asymptomatic at three years of follow-up. The authors suggest intravenous corticosteroids may be an option for disabling Sydenham’s chorea, but this is a single case, not a trial.
A 1993 letter notes that the American College of Rheumatology classification criteria for Henoch-Schönlein purpura require two of four features: palpable purpura, age ≤20 years, bowel angina, and wall granulocytes on biopsy. This classification has 87.1% sensitivity and 87.7% specificity. The authors of the criteria recognised that the diagnosis is primarily clinical and that biopsies are rarely necessary in children. What remains missing are controlled trials of any intervention for Henoch-Schönlein purpura itself, particularly for severe renal or gastrointestinal involvement, and prospective studies that stratify patients by age, severity, or biopsy findings.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Pediatrics · 1966 · 19 citations
Henoch-Schöenlein Purpura
AbstractA fulminating fatal case of Henoch- Schöenlein purpura is reported along with a review of the basic disease. Death was due to hemorrhage and necrosis in volving the entire gastro-intestinal tract. To the authors' knowledge, death due to total intestinal infarction in this disease has not been previously described. Addi tional autopsy findings included a necro tizing vasculitis involving skin, lungs and gastro-intestinal tract as well as focal necrosis of the liver and adrenal glands and a membranous glomerulonephritis.
Le Purpura De Schoenlein-Henoch. Etude Clinique Chez L’Adulte
AbstractSummary1. Twenty cases of Henoch-Schoenlein Purpura (HSP) are described in adult patients from 24 to 76 year old.2. The clinical characters are analyzed. The frequency distribution of the symptoms is the same as for the children : purpura (100 %), arthralgia (90 %), intestinal bleeding (57 %) and hematuria (57 %). The degree of the renal involvement determines the prognosis.3. The allergic etiology of the HSP was demonstrated with certainty in 3 of our patients. The causal antigens were respectively sulfa drugs, cow milk and extracts from B. coli.4. The recent advances made in the physiopathology of the disease are discussed.5. No particular therapy can be presently advocated with certainty.
Neurology India · 2009 · 2 citations · open access
Remission of concomitant Henoch-Schöenlein purpura and Sydenham chorea after intravenous corticosteroids
AbstractWe report a young girl who developed Henoch-Schoenlein purpura at the age of 11 years. Two weeks later she developed severe asymmetric choreic movements and behavioral disturbances. Sydenham s chorea was diagnosed based on the laboratory evidence and she was given intravenous methylprednisolone for five consecutive days. Both behavioral and movement disorder rapidly resolved. She was asymptomatic at three years of follow-up. The rapid resolution of choreic movements and behavioral disturbances in our patients suggests, intravenous corticosteroids may be an option in the treatment of Sydenham's chorea, more so when the movements are disabling.
AbstractIn Reply.— Classification criteria have been established by the American College of Rheumatology (ACR) for the diagnosis of Henoch-Schöenlein purpura (HSP). These criteria include palpable purpura, age ≤20 years, bowel angina, and wall granulocytes on biopsy. The presence of two of four criteria is required for classification with a reported 87.1 % sensitivity and 87.7% specificity. The authors of the criteria recognized that the diagnosis of HSP is primarily clinical and that biopsies are rarely necessary to diagnose HSP in children.1
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
